Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir

Full text
Author(s):
Fernandes Campos, Guilherme Rodrigues [1] ; Ward, Joseph [2, 3] ; Chen, Shucheng [2, 3] ; Bittar, Cintia [1] ; Vilela Rodrigues, Joao Paulo [4] ; Candolo Martinelli, Ana de Lourdes [5] ; Souza, Fernanda Fernandes [5] ; Leira Pereira, Leonardo Regis [2, 3] ; Rahal, Paula [1] ; Harris, Mark [2, 3]
Total Authors: 10
Affiliation:
[1] Sao Paulo State Univ, Inst Biosci Languages & Exact Sci, BR-15054000 Sao Jose Do Rio Preto, SP - Brazil
[2] Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire - England
[3] Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire - England
[4] Univ Sao Paulo, Ribeirao Preto Sch Med, BR-14049900 Ribeirao Preto, SP - Brazil
[5] Univ Sao Paulo, Ribeirao Preto Fac Pharmaceut Sci, BR-14040903 Ribeirao Preto, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: JOURNAL OF GENERAL VIROLOGY; v. 102, n. 1 2021.
Web of Science Citations: 0
Abstract

Hepatitis C virus (HCV) genotype 3 presents a high level of both baseline and acquired resistance to direct-acting antivirals (DAAs), particularly those targeting the NS5A protein. To understand this resistance we studied a cohort of Brazilian patients treated with the NS5A DAA, daclatasvir and the nucleoside analogue, sofosbuvir. We observed a novel substitution at NS5A amino acid residue 98 {[}serine to glycine (S98G)] in patients who relapsed post-treatment. The effect of this substitution on both replication fitness and resistance to DAAs was evaluated using two genotype 3 subgenomic replicons. S98G had a modest effect on replication, but in combination with the previously characterized resistance-associated substitution (RAS), Y93H, resulted in a significant increase in daclatasvir resistance. This result suggests that combinations of substitutions may drive a high level of DAA resistance and provide some clues to the mechanism of action of the NS5A-targeting DAAs. (AU)

FAPESP's process: 18/04678-5 - Analysis of Hepatitis C virus genotype 3 resistance to direct acting antivirals
Grantee:Guilherme Rodrigues Fernandes Campos
Support Opportunities: Scholarships abroad - Research Internship - Doctorate
FAPESP's process: 16/03807-0 - Study of resistance mutations to treatment with Directly Acting antivirals in patients infected with hepatitis C virus genotype 3
Grantee:Guilherme Rodrigues Fernandes Campos
Support Opportunities: Scholarships in Brazil - Doctorate